Ionis Pharmaceuticals Deep Dive Research Report

Report Date: March 11, 2026 | Prepared by: Ada Cockpit | Classification: Investor-Grade Research

$944M
FY2025 Revenue
+34%
YoY Growth
$12.5B
Market Cap
1,402
Employees
40+
Pipeline Programs

Executive Summary

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a global leader in RNA-targeted therapeutics, pioneering antisense oligonucleotide (ASO) technology for over three decades. The company develops medicines that target the root cause of disease by modulating RNA.

MetricValue
HeadquartersCarlsbad, California, USA
FoundedJanuary 10, 1989
Stock ExchangeNASDAQ: IONS
CEOBrett P. Monia, Ph.D.
Forward-Looking Disclaimer: This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section, including regulatory decisions, clinical trial outcomes, competitive dynamics, and market conditions.

Financial Overview

FY2025 Revenue Mix by Segment
R&D Collab $508M (54%) Commercial $436M (46%) Commercial Products R&D Collaboration
Revenue Growth Trajectory (2021-2025)
$1000M $800M $600M $400M $200M 2021 2022 2023 2024 2025 $810M $587M $788M $705M $944M

Key Financial Metrics (FY2025)

Metric FY 2025 FY 2024 YoY Change
Total Revenue $944 million $705 million +34%
Commercial Product Revenue $436 million N/A —
R&D Collaboration Revenue $508 million N/A —
Operating Loss (est.) ~$475-550M $475 million Similar
Q4 2025 EPS -$1.41 — —

Drug Portfolio Summary

Cardiometabolic & Rare Metabolic Diseases

Product Indication Revenue (FY25) Peak Sales P&L Owner
TRYNGOLZA (olezarsen) FCS; sHTG pending $108M >$2B Ionis
WAYLIVRA (volanesorsen) FCS (EU only) Minimal Limited Ionis

Neurology & Partner-Commercialized Products

Product Indication Revenue Peak Sales P&L Owner
SPINRAZA (nusinersen) SMA ~$1.7B (Biogen) $2B (declining) Biogen
WAINUA (eplontersen) ATTRv-PN Collab revenue $3.5-7B AstraZeneca/Ionis
DAWNZERA (donidalorsen) HAE Early launch $500M-1B Ionis

Top 5 CEO Focus Drugs

# Drug Indication Near-Term Catalyst Peak Sales
1 TRYNGOLZA FCS + sHTG sHTG FDA decision June 2026 >$2B
2 Eplontersen/WAINUA ATTR portfolio CARDIO-TTRansform H2 2026 $3.5-7B
3 Pelacarsen Elevated Lp(a) HORIZON results H1 2026 TBD (Novartis)
4 Bepirovirsen Chronic HBV Phase 3 positive; filing Q1 2026 TBD (GSK)
5 Zilganersen Alexander disease FDA decision 2026 $100-300M

R&D Pipeline

Program Indication Phase Partner Expected Readout
Olezarsen (sHTG) Severe Hypertriglyceridemia NDA Independent PDUFA: June 30, 2026
Zilganersen Alexander disease NDA Independent FDA decision 2026
Eplontersen ATTR-CM Phase 3 AstraZeneca H2 2026
Pelacarsen Elevated Lp(a) + CVD Phase 3 Novartis H1 2026
Bepirovirsen Chronic hepatitis B Phase 3 ✓ GSK Filing Q1 2026
ION582 Angelman syndrome Phase 3 Independent 2030
Ulefnersen FUS-ALS Phase 3 Otsuka TBD
Sapablursen Polycythemia vera Phase 2a ✓ Ono Phase 3: 2028

Competitive Landscape

Competitor Focus Area Key Products Market Cap (Mar 2026)
Alnylam Pharmaceuticals RNAi/siRNA therapeutics ONPATTRO, AMVUTTRA, GIVLAARI ~$42.5B
Arrowhead Pharmaceuticals RNAi therapeutics Pipeline-stage ~$5-8B
Sarepta Therapeutics Gene therapy, ASOs EXONDYS, ELEVIDYS ~$1.7B
Biogen Partner/competitor SPINRAZA, QALSODY ~$24B

Risks and Challenges

Risk Category Description Impact Level
Clinical/Regulatory CARDIO-TTRansform (ATTR-CM) trial results H2 2026 HIGH
Competitive SPINRAZA royalty erosion from Zolgensma/Evrysdi HIGH
Financial Sustained operating losses; $500-550M loss projected 2026 MEDIUM
Patent/Exclusivity SPINRAZA earliest generic entry Dec 2030 MEDIUM
Partner Dependency ~54% of revenue from R&D collaborations MEDIUM

Ada Patient Finder Analysis

Patient Finder Candidates (Score ≥6)

Drug Indication Score Key Diagnostic Insight
TRYNGOLZA FCS 9/10 24-year diagnostic delay; 5 physicians before diagnosis
WAINUA ATTR-PN 9/10 34-57% misdiagnosis rate; 3.5-year delay
WAINUA ATTR-CM 8/10 80-90% undiagnosed; 27-30 month delay
DAWNZERA HAE 8/10 Frequently misdiagnosed as allergic angioedema
TRYNGOLZA sHTG 6/10 3.6M diagnosed; value in risk stratification

Top Pitch Hooks

TRYNGOLZA for FCS: "Patients with FCS wait an average of 24 years and see 5 different physicians before receiving a correct diagnosis—often only after emergency hospitalization for acute pancreatitis. Ada's symptom checker can identify the pattern of recurrent severe abdominal pain plus a history of extreme triglyceride elevation, flagging potential FCS cases years earlier than current diagnostic pathways."
WAINUA for ATTR: "ATTR amyloidosis patients are misdiagnosed 34-57% of the time, consulting multiple specialists over 3-6 years before receiving the correct diagnosis. Ada can recognize the constellation of progressive neuropathy, bilateral carpal tunnel syndrome, and autonomic symptoms that should trigger ATTR workup—potentially shaving years off the diagnostic odyssey."
WAINUA for ATTR-CM: "Up to 90% of ATTR cardiomyopathy cases remain undiagnosed, with patients spending 27-30 months in the diagnostic wilderness. Ada can identify the 'red flag' pattern of bilateral carpal tunnel syndrome preceding unexplained heart failure—a combination that should prompt immediate ATTR evaluation."

Outlook and Valuation

Medium-Term Financial Targets

Metric 2025A 2026E 2028E
Revenue $944M $800-825M* Cash flow breakeven
Operating Loss ~$500M $500-550M ~Zero
Cash Runway $1.6B Sufficient Self-funding

*2026 guidance excludes $280M one-time sapablursen license fee received in 2025

Peer Valuation Comparison

Metric Ionis Alnylam Sarepta
Market Cap ~$12.5B ~$42.5B ~$1.7B
Enterprise Value ~$13.1B ~$37.8B ~$2.9B
Revenue (2025) $944M ~$2.2B ~$2.0B
P/S Ratio ~13x ~19x ~0.9x

References

  1. Ionis Pharmaceuticals. "Company History." Corporate website. Accessed March 2026.
  2. n-Lorem Foundation. "Stanley T. Crooke, M.D., Ph.D. Biography." 2025.
  3. Labiotech.eu. "Antisense Oligonucleotide Companies to Watch." 2025.
  4. Oligonucleotide Therapeutics Society. "The Personal Journey of Stanley Crooke." 2023.
  5. FDA. Drug Approval Letters. KYNAMRO, 2013.
  6. FDA. Drug Approval Letters. SPINRAZA, December 23, 2016.
  7. PR Newswire. "Ionis Completes Acquisition of Akcea Therapeutics." October 12, 2020.
  8. Las Vegas Sun. "Ionis Announces Changes to Board." March 9, 2026.
  9. Ionis. "Brett Monia Receives 2025 Lifetime Achievement Award." October 2025.
  10. OTS. "2019 Young Investigator Award: Holly Kordasiewicz, Ph.D."
  11. Ionis Pharmaceuticals. "Our Leadership." Corporate website. March 2026.
  12. MarketBeat. "Ionis CEO Teases Late-June Olezarsen Launch." February 28, 2026.
  13. PR Newswire. "Ionis and Royalty Pharma Agreement." January 2023.
  14. Benzinga. "AstraZeneca/Ionis Eplontersen FDA Approval." December 2023.
  15. BioPharma Dive. "Ionis DAWNZERA HAE Approval." August 2025.
  16. BioPharma Dive. "GSK Ionis Bepirovirsen Results." March 2026.
  17. Moomoo Finance. "Ionis Revenue by Geography." Financial data.
  18. Simply Wall St. "Ionis Pharmaceuticals Valuation Analysis." March 2026.
  19. AHA Journals. "FCS Prevalence Study." Circulation, 2019.
  20. Delve Insight. "Severe Hypertriglyceridemia Market Report." 2024.
  21. Rare Disease Advisor. "WAINUA (eplontersen) Overview." 2024.
  22. Indiana University. "ATTR Amyloidosis Diagnostic Delay Studies." 2024.
  23. Mordor Intelligence. "ATTR Treatment Market." 2025.
  24. Angelman Syndrome Foundation. "About Angelman Syndrome."
  25. NORD. "Alexander Disease." Rare Diseases Database.
  26. ClinicalTrials.gov. NCT04023552 (Lp(a)HORIZON).
  27. ClinicalTrials.gov. NCT04136171 (CARDIO-TTRansform).
  28. ClinicalTrials.gov. NCT06914609 (REVEAL - ION582).
  29. Stock Analysis. "Ionis Employee Count." 2026.
  30. Stock Analysis. "Ionis Revenue." 2026.
  31. Investing.com. "Ionis Q4 2025 Earnings Transcript." February 2026.
  32. Trading View. "Ionis Q4 2025 Results." February 2026.
  33. Companies Market Cap. "Ionis Market Cap." March 2026.
  34. YCharts. "Ionis Enterprise Value." 2026.
  35. Pharmaceutical Technology. "Biogen Q1 Revenue." Q1 2025.
  36. Grand View Research. "Nusinersen Market Forecast." 2025.
  37. Drug Patent Watch. "SPINRAZA Patent Information." 2026.
  38. GSK. "B-Well Phase III Trials Results." March 2026.
  39. PR Newswire. "Ionis Next-Gen Lp(a) Collaboration." July 2023.
  40. Fierce Biotech. "Novartis $60M Ionis Deal." July 2023.
  41. Companies Market Cap. "Alnylam Market Cap." March 2026.
  42. Companies Market Cap. "Sarepta Market Cap." March 2026.